Clinical trials: Transitional Cell Cancer of the Renal Pelvis and Ureter
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003342
- Testing
- filgrastim, carboplatin, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, and gemcitabine, work in different ways to stop the growth of tumor…
- Trial name
- NCT00623064
- Testing
- cisplatin, gemcitabine hydrochloride, lapatinib ditosylate
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
Phase II trial to study the effectiveness of trastuzumab in treating patients who have previously treated, locally advanced, or metastatic cancer of the urothelium.
- Conditions
- Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT00004856
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014144
- Testing
- gefitinib
- Where
- 95 sites in United States
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have metastatic…
- Trial name
- NCT00004203
- Testing
- oxaliplatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Bladder Cancer, Kidney Cancer
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00900276
- Testing
- immunologic technique, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
This phase IV trial tests the impact of standard of care enfortumab vedotin and pembrolizumab followed by removal of all or part of the bladder (cytoreductive cystectomy) and/or removal of all or part of the tube that carriers…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
- Trial name
- NCT06764095
- Testing
- Biospecimen Collection, Computed Tomography, Cystectomy
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Bladder Cancer, Brain and Central Nervous System Tumors
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma
- Trial name
- NCT00757614
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 14,000 people
- Sponsor
- Cancer Research UK
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma
Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies.
- Trial name
- NCT04672330
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- RenJi Hospital
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent cancer of the bladder or urinary tract.
- Conditions
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
- Trial name
- NCT00009867
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic…
- Trial name
- NCT00066352
- Testing
- bortezomib
- Where
- 15 sites in United States, Canada
- Sponsor
- University Health Network, Toronto
Urothelial Carcinoma
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence
The investigators evaluated the efficacy of a single early intravesical instillation of doxetaxel in the prevention of bladder recurrence after nephroureterectomy or distal ureterectomy for upper urinary tract urothelial…
- Trial name
- NCT03209206
- Testing
- Docetaxel
- Where
- South Korea
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Neoadjuvant Therapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma
This study is designed prospectively to investigate the safety and efficacy of neoadjuvant PD-1 monoclonal antibody combined with cisplatin-based chemotherapy in patients with locally advanced upper urinary tract urothelial…
- Trial name
- NCT04672317
- Testing
- Immunotherapy combined with chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Urothelial Carcinoma, Urothelial Carcinoma Bladder
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced…
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06823427
- Testing
- 9MW2821, Toripalimab (JS001 )
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Bladder Cancer, Urethral Cancer
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients…
- Trial name
- NCT00082719
- Testing
- Recombinant Interferon Alfa
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well bortezomib works in treating patients with advanced transitional cell carcinoma of…
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer
- Trial name
- NCT00072150
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma Ureteral Location
Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma
The aim of this study is to evaluate the feasibility, safety, and efficacy of MitoGel in the treatment of UTUC in a human subject with low-grade UTUC which is endoscopically unresectable or rapidly recurring, and in whom…
- Trial name
- NCT02701023
- Testing
- MitoGel
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well vorinostat works in treating patients with locally recurrent or metastatic cancer of…
- Conditions
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00363883
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)